Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

Documenti analoghi

• Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
  di: Fabio Efficace, et al.
  Pubblicazione: (2024)
• Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
  di: Francesca Vinchi, et al.
  Pubblicazione: (2024)
• Why Validation Substudies Matter
  di: Lindsay J. Collin, et al.
  Pubblicazione: (2026)
• MATURATION OF THE GONADS AND SEASONAL CYCLE OF THE PLANKTONIC LARVAE OF THE OPHIUROID AMPHIURA CHIAJEI FORBES
  di: Fenaux, Lucienne
  Pubblicazione: (1970)
• Impact of myelodysplasia‐related mutations on 2022 European LeukemiaNet genetic risk classification in de novo acute myeloid leukemia with normal karyotype
  di: Srija Shanker, et al.
  Pubblicazione: (2024)